KR20160037233A - 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브 - Google Patents

급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브 Download PDF

Info

Publication number
KR20160037233A
KR20160037233A KR1020167005392A KR20167005392A KR20160037233A KR 20160037233 A KR20160037233 A KR 20160037233A KR 1020167005392 A KR1020167005392 A KR 1020167005392A KR 20167005392 A KR20167005392 A KR 20167005392A KR 20160037233 A KR20160037233 A KR 20160037233A
Authority
KR
South Korea
Prior art keywords
hydrate
pharmaceutically acceptable
acceptable salt
decitabine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167005392A
Other languages
English (en)
Korean (ko)
Inventor
도로테아 루돌프
틸만 타우베
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51352490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160037233(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20160037233A publication Critical patent/KR20160037233A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167005392A 2013-07-26 2014-07-24 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브 Withdrawn KR20160037233A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361858802P 2013-07-26 2013-07-26
US61/858,802 2013-07-26
PCT/EP2014/065937 WO2015011234A1 (en) 2013-07-26 2014-07-24 Volasertib in combination with decitabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome ii

Publications (1)

Publication Number Publication Date
KR20160037233A true KR20160037233A (ko) 2016-04-05

Family

ID=51352490

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167005392A Withdrawn KR20160037233A (ko) 2013-07-26 2014-07-24 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브

Country Status (13)

Country Link
US (3) US20150031642A1 (OSRAM)
EP (1) EP3024465A1 (OSRAM)
JP (1) JP2016525530A (OSRAM)
KR (1) KR20160037233A (OSRAM)
CN (1) CN105407893A (OSRAM)
AU (1) AU2014295018A1 (OSRAM)
BR (1) BR112015031397A8 (OSRAM)
CA (1) CA2919294A1 (OSRAM)
CL (1) CL2016000024A1 (OSRAM)
EA (1) EA201600133A1 (OSRAM)
MX (1) MX2016001084A (OSRAM)
PH (1) PH12016500059A1 (OSRAM)
WO (1) WO2015011234A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092456A3 (ru) 2013-11-11 2021-09-30 Эмджен Инк. Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
JP2020535112A (ja) * 2017-08-01 2020-12-03 ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ
CN113082211A (zh) * 2021-04-14 2021-07-09 南方医科大学珠江医院 一种治疗npm1突变急性髓系白血病的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US9358233B2 (en) * 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia

Also Published As

Publication number Publication date
JP2016525530A (ja) 2016-08-25
CA2919294A1 (en) 2015-01-29
CL2016000024A1 (es) 2016-09-30
AU2014295018A1 (en) 2015-12-10
BR112015031397A8 (pt) 2018-01-30
CN105407893A (zh) 2016-03-16
US20170157159A1 (en) 2017-06-08
US20190240241A1 (en) 2019-08-08
MX2016001084A (es) 2016-04-25
BR112015031397A2 (pt) 2017-07-25
WO2015011234A1 (en) 2015-01-29
EA201600133A1 (ru) 2016-07-29
PH12016500059A1 (en) 2016-04-04
EP3024465A1 (en) 2016-06-01
US20150031642A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
CA2856646C (en) Combination treatment of cancer
JP2013543879A (ja) 急性骨髄性白血病を治療するための単独またはシタラビンとの組合せにおけるボラセルチブ
KR20210065962A (ko) 혈액학적 장애의 저강도 치료
US20190240241A1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i
KR20150090091A (ko) 볼라세르티브와의 병용 요법
JP6708634B2 (ja) 急性骨髄性白血病及び骨髄異形成症候群の併用療法ｉｉｉ
US20190240242A1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
CN117797149A (zh) 西达本胺联合r-chop的应用及联合药物
CN115038447A (zh) 用于治疗癌症的组合疗法
EP3641775B1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
US20220152074A1 (en) Treatment of hematological disorders
WO2022023514A1 (en) Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
US9956225B2 (en) Treatment of myelodysplastic syndrome
KR20130020945A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법
WO2024192139A1 (en) Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
Sekeres et al. Results of a Randomized Phase 3 Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS)
TW201306832A (zh) 用於治療骨髓發育不良症候群的組成物及方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid